{"id":"NCT01571362","sponsor":"Pfizer","briefTitle":"A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain","officialTitle":"A Multicenter, 12 Week, Double-blind, Placebo-controlled, Randomized Withdrawal Study To Determine The Efficacy And Safety Of Alo-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-release Capsules In Subjects With Moderate To Severe Chronic Low Back Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06","primaryCompletion":"2013-06","completion":"2013-06","firstPosted":"2012-04-05","resultsPosted":"2017-04-04","lastUpdate":"2017-04-04"},"enrollment":410,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Pain","Low Back Pain","Analgesia"],"interventions":[{"type":"DRUG","name":"ALO-02","otherNames":["oxycodone HCl and naltrexone HCl"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"ALO-02","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of the study is to determine the analgesic efficacy and safety of ALO-02 extended-release capsules, when compared to placebo, in subjects with moderate to severe chronic low back pain.","primaryOutcome":{"measure":"Change in Weekly Average Electronic Diary (eDiary) Numeric Rating Scale -Pain (NRS-Pain) Score From Randomization Baseline to Final 2 Weeks (Average of Weeks 11 and 12)","timeFrame":"Weeks 11 and 12","effectByArm":[{"arm":"ALO-02 To Placebo","deltaMin":1.23,"sd":0.179},{"arm":"ALO-02 To ALO-02","deltaMin":0.6,"sd":0.168}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0114"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":52,"countries":["United States"]},"refs":{"pmids":["31849032","31456431","29041942","25993547"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4531002"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":410},"commonTop":["Nausea","Constipation","Vomiting","Headache","Somnolence"]}}